ARTICLE | Deals
Mersana-GSK deal adds to immunostimulatory ADC momentum
The preclinical HER2-targeted ADC with a STING agonist payload is netting Mersana $100M up front and a path to co-commercialization
August 9, 2022 1:07 AM UTC
Mersana’s option deal for a preclinical candidate from its immunostimulatory ADC platform signals growing appetite for the next-generation take on the fast-growing modality.
The company will receive a $100 million upfront option purchase fee from partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for XMT-2056, a HER2-targeted ADC with a STING agonist payload. The upfront payment is the largest for a preclinical ADC deal to date, edging out the $90 million Sutro Biopharma Inc. (NASDAQ:STRO) received from Astellas Pharma Inc. (Tokyo:4503) in an immunostimulatory ADC deal announced June 27...